NCT03272334: An ongoing trial by University of Virginia
This trial is ongoing. It must report results 2 weeks, 1 day ago.
Full data
| Full entry on ClinicalTrials.gov | NCT03272334 |
|---|---|
| Title | A Phase I/II Study of Anti-CD3 X Anti-HER2/neu (Her2Bi) Armed Activated T Cells (ATC) and Pembrolizumab Combination Therapy in Women with Metastatic Breast Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 29, 2017 |
| Completion date | Nov. 30, 2024 |
| Required reporting date | Nov. 30, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |